Robigo与拜耳旗下Leaps公司宣布完成A轮融资，以推进旨在保护产量并降低成本的工程生物制品研发-动脉网

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

拜耳等信源发布 2026-09-17 21:08



可切换为仅中文







September

九月

2026

15:00 PM

下午 3:00

Europe/Amsterdam

欧洲/阿姆斯特丹

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

Robigo与拜耳旗下Leaps公司宣布完成A轮融资，以推进旨在保护作物产量并降低成本的工程化生物制剂研发

Summary

摘要

Robigo’s engineered microbes for combatting Sudden Death Syndrome in soybeans match the performance of commercially available chemistries at half the cost, targeting launch in 2028 / The second product in development, targeting the #1 fungal disease in lettuce and berries, increased yields by 3x compared to untreated control samples, targeting launch in 2029 / Robigo's ARGO™ platform cuts new product development from an industry standard of three to five years to under 20 months, proving a scalable engine behind the initial products.

Robigo公司针对大豆猝死综合征设计的工程微生物，其效果与市售化学农药相当，但成本仅为一半，计划于2028年推出；第二款在研产品针对生菜和浆果中排名第一的真菌病害，与未处理的对照样本相比，产量提高了三倍，计划于2029年推出；Robigo公司的ARGO™平台将新产品开发周期从行业标准的三到五年缩短至不到20个月，证明了其作为初始产品背后可扩展引擎的实力。

Cambridge, Mass., September 17, 2026

马萨诸塞州剑桥，2026年9月17日

– Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable without sacrificing performance.

– Robigo 是一家致力于开发无妥协生物解决方案以用于作物保护的生物技术公司，今日宣布完成由拜耳旗下 Leaps by Bayer 领投的 A 轮融资，Illumina Ventures、SVG Thrive、Congruent Ventures 和 Endeavor8 参与投资。本轮融资将加速其工程化微生物生物农药在美国的商业化上市，这些生物农药旨在对抗大豆及特作作物的真菌病害，在不牺牲性能的前提下实现经济可行性。

The round will also support Robigo’s pipeline expansion to target additional soil-borne pathogens in broadacre crops, tapping into an addressable market of $10 billion..

本轮融资还将支持 Robigo 拓展其产品管线，以针对大田作物中的其他土传病原体，从而切入规模达 100 亿美元的目标市场。

Biologicals, which have long been hailed as the next frontier in agriculture, add another tool to expand the farmer’s arsenal of technologies for targeted pest and disease control. The economic toll of crop disease is staggering, and new solutions to combat this are needed. Sudden Death Syndrome (SDS) in soybeans alone causes an estimated $200–$500 million in annual losses for U.S.

生物制剂长期以来被誉为农业的下一个前沿领域，它为农民提供了又一工具，以扩充其针对病虫害防控的技术 arsenal。作物病害造成的经济损失令人震惊，亟需新的解决方案来应对这一挑战。仅大豆猝死综合征（SDS）每年就给美国造成估计达2亿至5亿美元的损失。

soybean farmers, and effective chemistries are costly and limited. Meanwhile, fusarium wilt is currently the #1 disease problem for lettuce and berry growers, making Robigo’s solution an excellent addition to their crop protection toolbox..

大豆种植户而言，有效的化学药剂成本高昂且选择有限。与此同时，镰刀菌枯萎病目前是生菜和浆果种植者面临的首要病害问题，这使得Robigo的解决方案成为其作物保护工具库中的绝佳补充。

Robigo's solutions to address crop diseases are rooted in a fundamentally new approach that leverages synthetic biology to precisely engineer the genetics of living microbes, giving them the traits needed to consistently control pests and disease. The company’s ARGO™ platform delivers rapid programmability with computationally designed active ingredients, enabling novel modes of action that silence the pathogen’s essential genes.

Robigo 针对作物病害的解决方案源于一种全新的方法，该方法利用合成生物学对活体微生物的基因进行精确改造，赋予其稳定控制害虫和病害所需的性状。公司的 ARGO™ 平台通过计算设计的活性成分实现快速可编程性，从而开发出能够沉默病原体必需基因的新型作用机制。

The platform delivers unparalleled speed, shortening development from computational design through microbe engineering, lead validation, and field testing to under 20 months, compared with an industry norm of three to five years..

该平台提供无与伦比的速度，将从计算设计到微生物工程、先导化合物验证及田间试验的整个开发周期缩短至20个月以内，而行业常规周期为三到五年。

Robigo's engineered microbes are applied as a one-time treatment and continuously produce and deliver ARGO™-designed active ingredients where the plant needs them most. This approach provides season-long protection with no change to grower practices.

Robigo 的 engineered microbes 被用作一次性处理，持续生产并输送 ARGO™ 设计的活性成分到植物最需要的地方。这种方法在整个生长季节提供保护，且无需改变种植者的操作方式。

“At Robigo, we believe in building on nature’s foundation to engineer biological products that match or exceed the performance of today's chemistries. Growers shouldn't have to choose between a product that works and one that's affordable or sustainable,' said Dr. Andee Wallace, Founder & CEO of Robigo..

“在Robigo，我们相信依托自然的基础来开发生物产品，使其性能达到甚至超越当今化学产品的水平。种植者不应被迫在有效、可负担和可持续之间做出取舍。”Robigo创始人兼首席执行官Andee Wallace博士表示。

'The scalability of the ARGO™ platform is what sets Robigo apart,” said Dr. Juergen Eckhardt, EVP and Head of Leaps by Bayer. “They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens across broadacre crops. Robigo’s pipeline of crop protection programs targets urgent, devastating diseases and offers a strong complement to Bayer’s crop protection portfolio.

“ARGO™平台的可扩展性是Robigo脱颖而出的关键，”拜耳Leaps执行副总裁兼负责人Juergen Eckhardt博士表示。“他们不仅仅是在开发单一产品，而是在构建一个能够快速应对大田作物中多种土传病原体的引擎。Robigo的作物保护项目管线针对的是紧迫且破坏性极强的病害，为拜耳的作物保护产品组合提供了强有力的补充。”

Robigo is moving quickly to provide farmers with the tools they need to protect their livelihoods, reduce environmental impact, and ensure a more resilient food system.'.

Robigo 正在迅速行动，为农民提供他们所需的工具，以保护其生计、减少环境影响，并确保建立更具韧性的粮食系统。

Photos and videos are available in this

此提供照片和视频

folder

文件夹

。

About Robigo:

关于罗比戈：

Robigo is crop protection without compromise. Powered by its proprietary ARGO™ platform, Robigo engineers biological solutions that outperform synthetic chemistries while delivering healthier soils and supporting a more resilient food system.

Robigo 提供毫不妥协的作物保护方案。依托其专有的 ARGO™ 平台，Robigo 开发生物解决方案，其效果优于合成化学品，同时促进土壤健康，助力构建更具韧性的粮食体系。

www.robigo.bio

About Leaps by Bayer:

关于拜耳Leaps：

Leaps by Bayer aims to solve ten huge challenges or ‘Leaps’ through scientific breakthroughs. As the strategic investment unit of Bayer, Leaps has invested over $2.1 billion in more than 65 companies innovating emerging platforms and technologies in health and agriculture.

拜耳旗下的Leaps旨在通过科学突破解决十大重大挑战或“飞跃”。作为拜耳的战略投资部门，Leaps已向65多家创新健康与农业新兴平台及技术的公司投资超过21亿美元。

www.leaps.bayer.com

Find more information at

更多信息请访问

www.bayer.com

。

Forward-Looking Statements

前瞻性陈述

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本新闻稿可能包含基于拜耳管理层当前假设和预测的前瞻性陈述。各种已知和未知的风险、不确定性和其他因素可能导致公司未来的实际业绩、财务状况、发展或表现与本文给出的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳在其官方网站上公开的报告中讨论的内容。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

. 本公司不承担任何更新这些前瞻性陈述或使其保持一致的责任

them to future events or developments.

将它们与未来的事件或发展联系起来。

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

拜耳股份公司是一家在全球拥有运营子公司的控股公司。文中提及“拜耳”或“本公司”时，根据上下文需要，可能指代其一家或多家子公司。

Contact

联系方式

Kira Peikoff

基拉·佩科夫

Deputy Director Communications

通讯副总监

kira.peikoff@bayer.com

+1 973 791 3348

Downloads

下载

2026-0161e.pdf